Sensei Biotherapeutics is an immuno-oncology company that is dedicated to understanding and selectively interacting with the tumor microenvironment in order to tilt the immune system against cancer. We are leveraging our TMAb™ platform to develop highly selective therapeutics that have the potential to alter the relationship between host immune cells and cancer so that the tumor is recognized and treated as if it were an infection. Our team is comprised of lifelong learners striving for insight at the intersection of immunology, oncology and biology. We are driven to apply our scientific curiosity to the critical needs faced daily by people who are diagnosed with cancer and the physicians who treat them. We stay humble, always follow the data, and believe that our deep knowledge of cancer biology, the tumor microenvironment, and immunology will lead us to effective therapies.